Hanson Wade Intelligence

📣 𝗨𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗼𝗻 𝗔𝗗𝗖 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗡𝗲𝘅𝘁 𝗪𝗲𝗲𝗸 With the rapidly progression of Antibody-Drug Conjugates (ADCs) through clinical stages, the need to 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗲 𝗲𝘃𝗲𝗿𝘆 𝗽𝗵𝗮𝘀𝗲 𝗼𝗳 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴, has never been more urgent—whether it's conjugation, purification, scalability, or beyond. Join Merck Group, Amgen, and Zymeworks Inc., as we hear from some of the leading experts in cutting-edge companies in the space. They'll share their process development strategies to convert all the excitement into tangible ADC success! This webinar is organized by Hanson Wade Intelligence and made possible by our ADC manufacturing partner Cytiva 𝗗𝗮𝘁𝗲: 𝟭𝟬𝘁𝗵 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟬𝟮𝟰 𝗧𝗶𝗺𝗲: 𝟭𝟮 𝗣𝗠 𝗘𝗧 (𝟲 𝗣𝗠 𝗖𝗘𝗦𝗧) Register here and be part of the conversation 🔗 https://lnkd.in/eM3XxfPU 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝘁𝗵𝗶𝘀 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗶𝗻: ·      Approaches to scale up supply for early clinical studies ·      Advantages and disadvantages to integrated supply chains ·      Tech transfer strategies from developer to CDMO ·      Harmonising stakeholder needs across CMC, PD and manufacturing #ADCs #noveldrugconjugates #ADCinnovation #ADCclinicalsuccess #emergingADCs #cytiva #marketinsight #ADCmanufacturing #ADCprocessdevelopment #ADCCMC

Shortened Manufacturing for Auto CAR-T | All talk and no action? In the fast-paced life sciences space, staying ahead of innovation can make the difference between leading or lagging. Tracking emerging trends through metrics like publications, pipeline activity, and key players is crucial. Without this vigilance, companies risk missing out on disruptive technologies, key investments, or market shifts. On the flip side, tracking declining activity could reveal hurdles that offer a moment to reassess or pivot. Ultimately, staying informed is a safeguard and a strategy for seizing new opportunities. Take the buzz around shortened cell therapy manufacturing—how much of it is translating into real progress and adoption? Why is adoption happening at its current pace? What does this mean for companies already invested or considering entry into the space? Tracking the metrics above assists with answering these crucial questions. Our analyst team tracked the number of publications discussing shortened manufacturing as an indication for research activity level. The data shows that following the approval of Kymriah and Yescarta, the excitement in CART space translated into a substantial increase in published research starting in 2019, peaking in 2022, before plateauing to levels seen between 2019 and 2021. It is also interesting to note that the big pharma such as AstraZeneca and Novartis, that are driving the investments in this space. 𝗙𝗼𝗹𝗹𝗼𝘄 𝗼𝘂𝗿 Hanson Wade Intelligence 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗮𝗰𝗰𝗼𝘂𝗻𝘁 𝗶𝗳 𝘆𝗼𝘂 𝘄𝗼𝘂𝗹𝗱 𝗹𝗶𝗸𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗺𝗼𝗿𝗲 𝗰𝗼𝗻𝘁𝗲𝗻𝘁𝘀 𝗹𝗶𝗸𝗲 𝘁𝗵𝗶𝘀 𝗼𝗻𝗲! To stay ahead of the curve with indication landscapes, opportunity assessments, or other custom researches, visit our website at https://lnkd.in/e9yRCP4U Or Drop us an email at: intelligence@hansonwade.com #LifeSciences #CellTherapy #Innovation #CART #Pharma #Biotech #Kymriah #Yescarta #EmergingTrends #PipelineActivity #BigPharma #ResearchAnalysis #HealthcareInnovation #Biopharma #MarketIntelligence #Healthcare

𝗝𝗼𝗶𝗻 𝗨𝘀 𝗳𝗼𝗿 𝗮𝗻 𝗘𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗜𝗻𝘀𝗶𝗱𝗲 𝗟𝗼𝗼𝗸 𝗮𝘁 𝗥𝗡𝗔 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗧𝗿𝗲𝗻𝗱𝘀! Are you ready to dive into the future of RNA therapeutics? 🔬 𝗢𝘂𝗿 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗼𝗻 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟯𝟬, 𝟮𝟬𝟮𝟰, 𝗮𝘁 𝟵𝗮𝗺 𝗣𝗗𝗧 | 𝟭𝟮𝗽𝗺 𝗘𝗗𝗧 | 𝟰𝗽𝗺 𝗚𝗠𝗧 will explore the latest innovations shaping the landscape of RNA drug development. Register now to secure your spot! 🔗 https://ter.li/upz9fp Hosted by experts from Beacon and Hanson Wade Intelligence, you'll gain valuable insights into cutting-edge delivery systems, emerging technologies, and the commercial trends redefining the RNA market. Don't miss this opportunity to stay ahead of the curve in one of biotech's fastest-growing fields. #RNADrugDevelopment #RNA #RNAdeliverysystems #oligonucleotides #mRNA #Oligo

24 Hours to go! Don't miss your chance to quiz our experts on ADC Manufacturing. Do you also want to know: "How do you quantify residual liked payload and payload? Do you use RP-HPLC and or LCMS?" Tune in to hear what the consensus is. Registration link: https://lnkd.in/e9krFDPe

Last month, Science Journal Cell published the latest clinical results for a world-first allogeneic CAR-T therapy that sent autoimmune diseases into remission for 3 patients with severe myositis and systemic sclerosis We released a report on CAR Therapy landscape for autoimmune diseases earlier this year, you can find the report here: https://lnkd.in/eBSZJJud (Find the link to the clinical trial result paper in the comment section) #CARTherapy #AutoimmuneDiseases #InnovationInHealthcare #HWIUpdate #ClinicalTrials #BiotechInnovation #marketresearch #CART #Celltherapy

🔍 𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗘𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗼𝗳 𝗚𝗲𝗻𝗲𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝗠𝗼𝗱𝗶𝗳𝗶𝗲𝗱 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀: 𝟮𝟬𝟮𝟯 𝘃𝘀. 𝟮𝟬𝟮𝟰 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 🧬   The approval of over 20 genetically engineered cell therapies, including the recent approval of the first GM cell therapy 𝗧𝗘𝗖𝗘𝗟𝗥𝗔® for treating solid tumor indications, developed by Adaptimmune, showcases the field's promise. However, it raises an important question: Despite a seemingly stable market with some successes, what dynamics are influencing pipeline activity, and is the landscape truly characterized by high rewards?   Our analysis of the number of pipeline assets and biopharma companies actively developing these therapies in Q3 2023 vs. Q3 2024 reveals both promise and complexity in this field.   Monitoring pipeline changes reveals market trends and provides insights into actual activities beyond high-level numbers. It uncovers challenges, identifies opportunities, and helps pinpoint successful and failing assets or companies. This information is essential for informed competitive intelligence and investment strategies.   𝗙𝗼𝗹𝗹𝗼𝘄 𝗼𝘂𝗿 Hanson Wade Intelligence 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗮𝗰𝗰𝗼𝘂𝗻𝘁 𝗶𝗳 𝘆𝗼𝘂 𝘄𝗼𝘂𝗹𝗱 𝗹𝗶𝗸𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗺𝗼𝗿𝗲 𝗰𝗼𝗻𝘁𝗲𝗻𝘁𝘀 𝗹𝗶𝗸𝗲 𝘁𝗵𝗶𝘀 𝗼𝗻𝗲! To stay ahead of the curve with indication landscapes, opportunity assessments, or other custom researches, visit our website at https://lnkd.in/e9yRCP4U Or Drop us an email at: intelligence@hansonwade.com The data below was collected using access the Beacon database. #celltherapy #engineeredtherapy #BiotechInnovation #BiotechTrends #MedicalResearch #HealthcareInnovation #Biopharma #lifescience

🔬As promised 𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐀𝐃𝐂𝐬 (Part 2) 𝐢𝐬 𝐇𝐞𝐫𝐞 : 𝐒𝐢𝐭𝐞-𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐂𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐢𝐨𝐧 (𝐒𝐒𝐂) 𝐢𝐬 𝐓𝐚𝐤𝐢𝐧𝐠 𝐎𝐯𝐞𝐫! 🌟 The latest data shows that Site-Specific Conjugation (SSC) technologies are rapidly outperforming traditional stochastic conjugation methods in the ADC space. While stochastic conjugation has seen no new assets since 2022, SSC has experienced explosive growth, with a 3-year CAGR that is reshaping the future of Antibody-Drug Conjugates. 🔬 Forerunners such as ConjuAll (Ligachembio), GlycoConnect (Synaffix BV), and iLDC® (GeneQuantum Healthcare (Suzhou) Co., Ltd) lead the way, with robust 3-year CAGR of 19%, 24% and 33% respectively! 📈 Key Insights: SSC technologies are projected to dominate the future of ADCs. Companies are increasingly moving towards SSC due to its precision and higher success rates. The shift is undeniable – SSC is on track to replace outdated stochastic methods, with a significant surge in asset development and approvals. 👩🔬 Interested in staying ahead of the curve? Follow Hanson Wade Intelligence for more insights as we bring more niche market insights on the ADC space. This analysis was made possible with Beacon data. #ADCTherapies #SiteSpecificConjugation #BiotechInnovation #PharmaTrends #PrecisionMedicine #Oncology #ClinicalDevelopment

🔬As promised 𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐀𝐃𝐂𝐬 (Part 2) 𝐢𝐬 𝐇𝐞𝐫𝐞 : 𝐒𝐢𝐭𝐞-𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐂𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐢𝐨𝐧 (𝐒𝐒𝐂) 𝐢𝐬 𝐓𝐚𝐤𝐢𝐧𝐠 𝐎𝐯𝐞𝐫! 🌟 The latest data shows that Site-Specific Conjugation (SSC) technologies are rapidly outperforming traditional stochastic conjugation methods in the ADC space. While stochastic conjugation has seen no new assets since 2022, SSC has experienced explosive growth, with a 3-year CAGR that is reshaping the future of Antibody-Drug Conjugates. 🔬 Forerunners such as ConjuAll (Ligachembio), GlycoConnect (Synaffix BV), and iLDC® (GeneQuantum Healthcare (Suzhou) Co., Ltd) lead the way, with robust 3-year CAGR of 19%, 24% and 33% respectively! 📈 Key Insights: SSC technologies are projected to dominate the future of ADCs. Companies are increasingly moving towards SSC due to its precision and higher success rates. The shift is undeniable – SSC is on track to replace outdated stochastic methods, with a significant surge in asset development and approvals. 👩🔬 Interested in staying ahead of the curve? Follow Hanson Wade Intelligence for more insights as we bring more niche market insights on the ADC space. This analysis was made possible with Beacon data. #ADCTherapies #SiteSpecificConjugation #BiotechInnovation #PharmaTrends #PrecisionMedicine #Oncology #ClinicalDevelopment

🔬 𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐀𝐃𝐂𝐬 𝐢𝐬 𝐇𝐞𝐫𝐞 (Part 1): 𝐒𝐢𝐭𝐞-𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐂𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐢𝐨𝐧 (𝐒𝐒𝐂) 𝐢𝐬 𝐓𝐚𝐤𝐢𝐧𝐠 𝐎𝐯𝐞𝐫! 🌟 It is no secret that 𝐒𝐢𝐭𝐞-𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐂𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐢𝐨𝐧 (𝐒𝐒𝐂) is rapidly replacing stochastic conjugation as the industry standard. While stochastic conjugation has seen no new assets since 2022, SSC is soaring with a 23% 𝐂𝐀𝐆𝐑 and is poised to dominate the field. 🚀 SSC offers superior precision, stability, and effectiveness—making it the technology of choice for a growing number of companies. Despite representing a smaller fraction of approved ADC assets today, SSC’s growth rate signals that it will soon lead the charge in the next generation of cancer treatments. Stay ahead of the curve by 𝐅𝐨𝐥𝐥𝐨𝐰 𝐨𝐮𝐫 𝐋𝐢𝐧𝐤𝐞𝐝𝐈𝐧 𝐩𝐚𝐠𝐞 𝐚𝐬 𝐰𝐞 𝐰𝐢𝐥𝐥 𝐬𝐡𝐚𝐫𝐞 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐝𝐚𝐭𝐚 𝐢𝐧𝐭𝐨 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐒𝐒𝐂 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 (𝐏𝐚𝐫𝐭 𝟐) such as: ConjuAll 리가켐바이오 Ligachembio), GlycoConnect (Synaffix BV), and iLDC® (GeneQuantum Healthcare (Suzhou) Co., Ltd Healthcare) that are revolutionizing targeted therapies! The analysis was made possible with data from Beacon #ADCTherapy #SiteSpecificConjugation #BiopharmaInnovation #PharmaTrends #CancerResearch #ClinicalDevelopment #PrecisionMedicine #Oncology #Biotech

🚨 Only 1 day to go until our webinar on the latest advancements in ADCs! Novel drug conjugates are emerging as a transformative force in the ADC space so don't miss this chance to dive deep into emerging trends and cutting-edge insights with our expert speakers, Yu-Shin Hsu and Callum Angus. ⏳ Last chance to register: 🔗 https://ter.li/rzae33 Whether you're in drug development or clinical research, this is the event to stay ahead! #ADCs #noveldrugconjugates #ADCinnovation #ADCclinicalsuccess #emergingADCs Hanson Wade Intelligence